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Abstract
Background: Dengue virus (DENV) is the most common vector-borne viral infection worldwide with approximately
390 million cases and 25,000 reported deaths each year. MicroRNAs (miRNAs) are small non-coding RNA molecules
responsible for the regulation of gene expression by repressing mRNA translation or inducing mRNA degradation.
Although miRNAs possess antiviral activity against many mammalian-infecting viruses, their involvement in DENV
replication is poorly understood.
Methods: Here, we explored the relationship between DENV and cellular microRNAs using bioinformatics tools.
We overexpressed miRNA-133a in Vero cells to test its role in DENV replication and analyzed its expression using
RT-qPCR. Furthermore, the expression of polypyrimidine tract binding protein (PTB), a protein involved in DENV
replication, was analyzed by western blot. In addition, we profiled miRNA-133a expression in Vero cells challenged
with DENV-2, using Taqman miRNA.
Results: Bioinformatic analysis revealed that the 3' untranslated region (3'UTR) of the DENV genome of all four
DENV serotypes is targeted by several cellular miRNAs, including miRNA-133a. We found that overexpression of
synthetic miRNA-133a suppressed DENV replication. Additionally, we observed that PTB transcription , a miRNA-133a
target, is down-regulated during DENV infection. Based in our results we propose that 3'UTR of DENV down-
regulates endogenous expression of miRNA-133a in Vero cells during the first hours of infection.
Conclusions: miRNA-133a regulates DENV replication possibly through the modulation of a host factor such as PTB.
Further investigations are needed to verify whether miRNA-133a has an anti-DENV effect in vivo.
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Background
Dengue virus (DENV) causes an estimated 390 million
infections per year, making dengue the most prevalent
mosquito-borne viral infection worldwide [1]. DENV be-
longs to the Flaviviridae family and four antigenically
distinct virus serotypes designated 1 to 4 (DENV 1–4)
have been identified to date. Infection with any of the
four DENV serotypes can lead to a broad spectrum of
clinical symptoms ranging from acute febrile illness to
life-threatening complications such as hemorrhages and
hypovolemic shock [2, 3]. Neither a vaccine nor an
antiviral drug therapy exists to prevent or treat dengue
diseases.
The genome of DENV consists of an 11-kilobase-long
single-stranded positive sense RNA molecule, encoding
one open reading frame (ORF) flanked by a 5′ untrans-
lated region (UTR) and a 3′UTR. The viral RNA is
translated as a single polyprotein that is cleaved by a
combination of host cell enzymes and the viral NS2B-3
protease complex to produce three structural (C, prM/
M, and E) and seven nonstructural (NS1, NS2A, NS2B,
NS3, NS4A, NS4B, and NS5) proteins [4]. In addition,
the flavivirus RNA produces two functional non-coding
RNAs derived from the 3′UTR; the subgenomic flavivi-
rus RNA (sfRNA) and KUN-miR-1 (reviewed in: [5]).
Interestingly, Schnettler et al., (2012) demonstrated that
sfRNA efficiently suppresses both the siRNA- and
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microRNA (miRNA)-induced RNAi pathway in mam-
malian and insect cells [6].
Small RNAs, such as miRNAs, are known to direct
post-transcriptional regulation of gene expression [7].
MiRNAs can be derived from host or viral RNAs and
can participate in a wide range of biological processes
including proliferation, cell development, apoptosis and
host defense [7, 8]. Host-derived miRNAs from plants,
nematodes, fungi and animals have antiviral activity
against many viral infections [9–11]. On the other hand,
virus-derived miRNAs regulate host and/or viral gene
expression in order to support viral replication [12]. The
positive or negative effect of cellular or viral miRNAs on
virus replication is either caused by a direct interaction
of the miRNA with the genome of the virus, or by regu-
lation of cellular factors that are important in virus repli-
cation [13–15].
Host miRNAs exhibit a variety of effects on the life
cycle of DENV. For example, incorporation of the
miRNA recognition element (MRE) for the hepatic-
specific miR-122 in the 3′ UTR of DENV-RNA was
found to suppress viral replication in transfected cells
[16]. Similarly, the insertion of the MRE for the
hematopoietic specific miR-142 into the DENV-2 gen-
ome restricts replication of the virus in dendritic cells
and macrophages, but not in non-hematopoietic cell
types [17]. In addition, experiments using a chimeric
DENV/TBEV (C, prM, E from Tick-borne encephalitis
virus), showed that the inclusion of the MRE for the
brain-expressed miR-9 and miR-124a reduced access of
the virus to the central nervous system thereby inhibit-
ing the development of lethal encephalitis in mice [18].
Also, miR-30e* suppresses DENV replication by promot-
ing interferon (IFN) production through the NF-κB
pathway [19]. Furthermore, overexpression of Let-7c
miRNA in Huh7 cells was found to decrease the infect-
ivity of DENV [20]. Lastly, overexpression of miR-548 g-
3p interferes with DENV translation and suppresses
replication of all four DENV serotypes [21].
On the other hand, reports also show that miRNAs
support DENV replication. For example, DENV in-
creases the expression level of miR-146a, thereby sup-
porting viral replication by dampening IFN production
[22]. Infection with DENV also changes the miRNA-
expression profile of PBMCs [23]. However, the impact
of the miRNA pathway on DENV infection requires fur-
ther investigation. This becomes more important if we
consider that DENV encodes functional miRNAs/viral
small RNAs and one of them targets specifically the
virus nonstructural protein 1 gene [24]. In this study we
investigated the role of miRNA-133a during DENV
infection. We found that overexpression of synthetic
miRNA-133a suppressed DENV replication, likely
through interference with polypyrimidine tract binding
protein (PTB) expression. Furthermore, our data shows
that all four DENV serotypes down-regulate the expres-
sion of miRNA-133a during the first 24 h post-infection




To identify cellular miRNAs with candidate target sites in
the 3′UTR of DENV RNA, the reference genomes of all 4
serotypes were downloaded from GeneBank (Accession
number: DENV-1 NC_001477; DENV-2 NC_001474;
DENV-3 NC_001475; DENV-4 NC_002640) and analyzed
using MicroInspector [25]. Microinspector and RNA hy-
brid are free algorithms available at their respective web-
sites (ncbi.nlm.nih.gov/pubmed/15980566 and http://
bibiserv.techfak.uni-bielefeld.de/rnahybrid/). MicroInspec-
tor allows the prediction of microRNA elements (MREs)
for all the human miRNAs reported in the miRBase. Since
the 3′UTR sequence is moderately conserved [26] and
considering that a functional miRNA target site would
likely be conserved among the 4 serotypes, only those
common target sites to the 4 reference sequences were se-
lected. Then, the findings of the MicroInspector algorithm
were confirmed using the RNAhybrid program [27]. RNA-
hybrid takes into account not only the presence of a com-
plementary sequence of the seed of the miRNA, but also
the secondary structure that the miRNA-target duplex ac-
quires when the two RNAs interact, as well as their
thermodynamic stability.
Cell lines
The mosquito C6/36 HT cell line was obtained from the
ATCC and cultured as previously described [28]. Vero
cells were obtained from the ATCC ( CCL-81) and
grown in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10 % V/V heat-inactivated fetal bo-
vine serum (FBS), 4 mM L-glutamine, and 10 units/ml
Penicillin/ 0.1 mg/ml Streptomycin (Sigma-Aldrich
Chemical Co, MO, USA), at 37 °C in an atmosphere of
5 % CO2.
Virus stocks and titration
Clinical isolates of DENV-1 (strain Bga-07), DENV-2
(strain 109–05) and DENV-4 (strain Bga-06) were ob-
tained from patients with dengue hemorrhagic fever
from Antioquia, Colombia (kindly provided by Dr. Díaz
F.J, Grupo Inmunovirología, Facultad de Medicina,
Universidad de Antioquia) and used for 3′UTR cloning.
The reference strain of DENV-1, DENV-2 New Guinea
C (NGC), DENV-3 and DENV-4 were provided by the
Center for Disease Control (CDC, CO, USA). Viral
stocks were obtained by inoculating the viruses to a
monolayer of C6/36 HT cells in a 75-cm2 tissue culture
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flask with the virus at a multiplicity of infection (MOI)
of 0.05 diluted in 1 ml of L-15 medium supplemented
with 2 % FBS. After 3 h of adsorption, 10 ml of L15
medium supplemented with 2 % FBS were added and
the cells were cultured for 5 days at 34 °C without CO2.
The supernatant was removed from the cells and centri-
fuged for 5 min at 1800 rpm to pellet cellular debris,
and then aliquoted for storage at −70 °C for future use.
Since titration of DENV by plaque assays is time-
consuming and not suitable for strains that do not
plaque, virus titration was performed by flow cytometry,
as previously described [29]. Briefly, the C6/36 HT cells
were seeded in 12-well plates and cultured overnight at
34 °C without CO2. Then, they were infected with 10-
fold serial dilutions of the virus and at 24 hpi, cells were
harvested and resuspended in PBS. For flow cytometry
analyses, the cells were fixed using a Fixation/
Permeabilization buffer (eBioscience, CA, USA), centri-
fuged, washed twice with PBS and stained with the mono-
clonal antibody 4G2 (Millipore, Darmstadt, Germany). A
secondary antibody, fluorescein isothiocyanate (FITC)-la-
beled goat anti-mouse IgG antibody (Invitrogen, Life
Technologies, CA, USA) was used. Cells were analyzed on
a FACScan flow cytometer using the FACSdiva software.
The percentage of infected cells in each sample and the
total number of cells seeded per well were used to calcu-
late the final titer of the virus.
Plasmid construction
The 3′ UTRs of DENV-1, −2 and −4 were amplified by
PCR from viral RNA obtained from cell culture superna-
tants. For all 3′ UTRs, cDNA was synthesized using 200
U/μl SuperScript III RT (Thermo Scientific, NH, USA)
in the presence of specific primers (forward: 5′
GAATTCGTAGGTGCGGCTCATTGATTGGGCTAAC
3′ that contains a stop codon (bold), and reverse: 5′
GTCGACGAACCTGTTGATTCAACAGCACC 3′). Re-
striction site for EcoRI and SalI (underlined) were incor-
porated during amplification at the 5′end of the forward
and reverse primers, respectively. Transcription was
conducted with 50 U/μl HotStartTaq (Thermo Scientific,
NH, USA) using the same pair of primers. PCR products
were purified with the QIAquick PCR Purification Kit
(Qiagen, Hilden, Germany), according to the manufac-
turer’s recommendations, and cloned into pEGFP-C1
(Clontech, CA, USA), using the EcoRI and SalI enzymes
(Thermo Scientific, NH, USA), to obtain a GFP con-
struct bound to the 3′UTR of DENV-RNA. Cloning was
verified by restriction assay and sequencing; the con-
structs generated are designated pGUD1, pGUD2 and
pGUD4 for the DENV-1 3′UTR; DENV-2 3′UTR, and
DENV-4 3′UTR, respectively. Despite our best efforts
the 3′ UTR of DENV-3 could not be amplified from
viral RNA from the DENV-3 isolates that we had
available.
miRNA-133a overexpression and evaluation of miRNA-
133a antiviral activity
To assess the effect of miRNA-133a on DENV-2 replica-
tion, Vero cells were seeded at a density of 4x105 cells/
well in 12-well cell culture plates. The following day,
cells were transfected with synthetic miRNA-133a
mimics or with miRNA-133a antisense mimics at a final
concentration of 50 nM/well (Ambion, TX, USA), using
DharmaFect (Thermo Scientific, NH, USA) according to
manufacturer’s instructions. At 24 h post-transfection,
cells were infected with DENV-2 strain NGC at a MOI
of 3 per cell, following the procedure described above.
At the indicated time points, cell monolayers were har-
vested and the percentage of infection was measured by
flow cytometry. Cell supernatants were used for viral
RNA purification, and viral RNA copy number was
assessed by RT-qPCR.
Quantitation of DENV infection
At the indicated time points post-infection, Vero cells
were harvested and analyzed by flow cytometry as de-
scribed above. The infected cells are expressed as the
percentage of infected cells over the total number of
cells analyzed.
Quantitation of viral RNA copy number
Viral RNA was extracted from culture supernatants
using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden,
Germany), according to manufacturer’s instructions. The
viral copy number was estimated by RT-qPCR using
DENV-2-specific primers (forward: 5′ CAATATGCTG
AAACGCGAGAGAAA 3′ and reverse: 5′CCCCATCT
ATTCAGAATCCCTGCT 3′),as were previously de-
scribed [30]. The calculation of the genomic RNA copy
number was performed based on a standard curve, as
previously described [31].
DENV infection of Vero cells and miRNA-133a expression
Vero cells were seeded at a density of 4x105 cells/well in
12-well cell culture plates. The following day, cell culture
medium was removed and DENV-1, DENV-3, DENV-4
(Centers for Disease Control and Prevention, CDC, GA,
USA) or DENV-2 NGC, was added to give an estimated
MOI of 3. Cells were incubated with the inoculum for
3 h at 37 °C with 5 % CO2 with gentle agitation each
30 min to allow virus adsorption. Then, medium was re-
moved and cells were washed twice with PBS 1X, and
fresh DMEM supplemented with 2 % FBS was added
and incubated for 8, 16, 24, 32, 48 and 72 h at 37 °C
with 5 % CO2. At the indicated time points, cells were
harvested and total RNA was extracted using Trizol
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reagent (Invitrogen, CA, USA) and the expression of en-
dogenous miRNA-133a was assessed by quantitative RT-
PCR (RT-qPCR).
pGUD1, pGUD2 and pGUD4 transient transfection
Vero cells were seeded at a density of 2x105 cells/well in
24-well plates and immediately transfected using 2 μg of
pGUD1, pGUD2 and pGUD4 and 2 μl of Lipofectamine
2000 reagent (Invitrogen, CA, USA), according to manu-
facturer’s instruction. After 5 h, the transfection medium
was removed and replaced by fresh DMEM supple-
mented with 2 % FBS and incubated for 12, 24, 48 and
72 additional hours. At the indicated time points, cells
were harvested and total RNA extraction was performed
using the Trizol reagent (Invitrogen, CA, USA) following
manufacturer’s instructions. The RNA concentration
was measured using a NanoDrop spectrophotometer
(Nano Drop Technologies, CA, USA). Expression of en-
dogenous miRNA-133a was determined using a Taqman
miRNA assay (Applied Biosystems, CA, USA). Reverse
transcription was carried out using 10 ng RNA to pro-
duce cDNA. RT-qPCR reactions were performed in trip-
licates with each cDNA template on the Bio-Rad CFX96
real-time Detection System (Bio-Rad, CA, USA), using
the SYBR green Master Mix (Thermo Scientific). Ct
(Cycle-threshold) values were calculated for each reac-
tion and normalized to an uninfected control and to the
18S RNA (ΔΔCt) to obtain the fold change. The trans-
fection efficiency was verified 24 h post-transfection
(hpt) by assessing the expression of GFP by fluorescence
microscopy.
miRNA-133a and DENV infection alter the expression of
PTB mRNA
To assess the effect of miRNA-133a on PTB mRNA ex-
pression, Vero cells were seeded at a density of 8x105
cells/well in 6-well cell culture plates. The following day,
cells were transfected with 50 or 100 μM synthetic
miRNA-133a mimics or with the miRNA-133a mimic
inhibitor (Ambion, TX, USA). To determine the effect of
DENV-2 on PTB expression, Vero cells were challenged
with DENV-2 and the expression of PTB was evaluated
12, 24 and 48 hpi by western blot. Alternatively, Vero
cells were transfected with synthetic miRNA-133a
mimics and challenged with DENV-2 24 h later. Then
PTB expression level was determined by western blot at
12, 24 and 48 h later.
Western blot analysis
At the respective times, cells were lysed with a lysis solu-
tion (Applied Biosystems, CA, USA) and the protein
concentration was determined using a BCA Protein
Assay kit (Pierce, Thermo scientific, NH, USA). Equal
amounts of sample lysate were separated using 10 %
SDS-PAGE and transferred onto a nitrocellulose mem-
brane. A primary monoclonal antibody against PTB
(Invitrogen, CA, USA) or GFP (Roche) and a secondary
anti-mouse IgG antibody conjugated with horseradish
peroxidase (HRP) (Santa Cruz Biotechnology, CA, USA)
were used. Finally, signals were detected using the
chemiluminescence ECL™ detection system (Pierce).
Statistical analysis
For all assays three independent experiments were car-
ried out and the data are presented as median with the
range. Statistical significance was determined with the
two-way Anova test with a confidence interval of 95 %.
Results
3′ UTR of DENV-1 to −4 contains potential cellular miRNAs
binding sites
As reported previously, human miRNAs can target viral
genomes [13, 14, 32]. Therefore, we first sought to inves-
tigate whether the 3’UTR of DENV RNA contains po-
tential miRNA binding sites, using MicroInspector
software [25]. The sequences of the 3′UTRs plus 374
nucleotides of the coding region of NS5 from all four
dengue serotypes were aligned. A total of 108 miRNAs
for DENV-1, 80 for DENV-2, 94 for DENV-3 and 89 for
DENV-4 were predicted to target the 3′UTR (Additional
file 1). Since the 3′UTR sequence is moderately con-
served [26] and with the hypothesis that a functional
miRNA target site would be conserved among all four
DENV serotypes, only those target sites common to the
4 reference sequences were selected. In total, 13 miR-
NAs fulfilled these criteria (Table 1). Interestingly, most
of the target sites localized to a single region, highlight-
ing a “hotspot” of potential MREs (Fig. 1). The findings
of the MicroInspector algorithm were then confirmed
using the RNAhybrid program [27]. RNAhybrid con-
siders the presence of a complementary sequence of the
seed of the miRNA, the secondary structure that the
miRNA-target duplex acquires when the two RNAs
interact, as well as their thermodynamic stability.
The bioinformatic analysis with RNAhybrid predicted
a miRNA-133a target sequence in the “hotspot” of the
3′UTR (Fig. 1a). The interaction between the miRNA
and the target RNA fulfills the seed sequence rule: per-
fect hybridization of bases 2–8 or 2–9 from the 5′ end
of the miRNA known as 7mer-A1, with the target RNA
[7]. Consistently, our bioinformatic analysis predicted a
miRNA-133a binding site in the 3′UTRs of all four sero-
types of DENV (Fig. 1b). Specifically, the target sequence
localizes to a loop of the 3′UTR known as the 3′SL,
which contains the elements known as 3′CS (nt 10620
to 10628) and 3′UAR (nt 10642 to 10657; Fig. 1c), both
required for genome circularization and viral viability.
Interestingly, miRNA-133a has been reported to target
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Table 1 miRNAs predicted to target a conserved region of DENV-1 to 4 3'UTR
miRNA DENV1 DENV2 DENV3 DENV4
miR-let-7a-2-star 10645, 10465 10451 10438 10374
miR-let-7c 10640 10628 10612 10554
miR-1254 10659 10647 10631 10573
miR-1290 10632 10620 10604 10546
miR-133a 10626 10614 10598 10540
miR-16 10689 10677 10661 10603, 10606
miR-199a-5p 10616 10547 10588 10530
miR-199b-5p 10616 10604 10588 10530
miR-330-5p 10569, 10628 10616 10600 10542, 10485
miR-484 10633 10621 10605 10547
miR-744 10590, 10634 10623 10531, 10562, 10607 10549, 10318
miR-769-5p 10641 10629 10613 10555




Fig. 1 Human miRNA-133a is predicted to target the 3'UTR of DENV. Using sequence alignment and Microinspector analysis, a miRNA-
133a target sequence was predicted within the DENV 3'UTR sequence, which fulfills the seed sequence rule (perfect hybridization of bases
2–8 or 2–9 from the 5' end of the miRNA with the target RNA) plus binding in a 7mer-A1 fashion (a). The predicted target sequence is
present in all four DENV serotypes (b). The location of the target sequence is in a loop of the 3'UTR known as the 3'SL, that contains the
elements known as 3'CS and 3'UAR (c)
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the PTB mRNA (Additional file 2) [33, 34], a cellular
protein that binds to the 3′ and 5′UTR of the ssRNA of
DENV and is required for viral replication and transla-
tion [35–37].
To further determine whether miRNA-133a has a
functional effect on these putative binding sites, and if
indeed this miRNA interacts with the 3′UTR of DENV
RNA, we inserted the 3′UTR sequence of DENV1,
DENV-2 or DENV-4 RNAs into the 3′ terminus of the
GFP reporter gene in pEGFP-C1. Each construct
(pGUD1, pGUD2 and pGUD4) was used for co-
transfection with the synthetic miRNA-133a mimic in
Vero cells and GFP expression was determined (Fig. 2).
The results showed that miRNA-133a decreased the ex-
pression of GFP as determined by fluorescence micros-
copy (Fig. 2a) and western blot analysis (Fig. 2b and c).
These results are consistent with our bioinformatic ana-
lysis and suggest that miRNA-133a interacts with the 3′
UTR of all four DENV serotypes.
miRNA-133a overexpression suppresses DENV-2
replication
Next, we determined if miRNA-133a modulates DENV
infection in Vero cells. Synthetic miRNA-133a or inhibi-
tors of miRNA-133a were transfected in Vero cells and
at 24 hpi cells were challenged with DENV-2 at a MOI
of 3. Viral RNA copies were quantified by RT-qPCR and
the percentage of infected cells was determined by flow
cytometry (using the 4G2 antibody), at 12, 24, 48 and 72
hpi . As shown in Fig. 3a, during the first 24 hpi, overex-
pression of miRNA-133a did not influence the percent-
age of infected cells. The percentage of infected cells
A
B C
Fig. 2 MiRNA-133a alters the expression of GFP-fused to the DENV RNA 3'UTR. Vero cells were co-transfected with pGUD1, pGUD2, pGUD4 or
synthetic miRNA-133a mimics and 24 h later, the expression of GFP was assessed by fluorescence microscopy (a) and western blot (b). Actin was
used as a loading control. Semi-quantitative data of the western blots were assessed using Image J (c). A representative experiment is shown. In
total three experiments were performed
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was however lower at 48 hpi, and reached significance at
72 hpi. At 72 hpi, the number of infected cells was 80 %
reduced when compared to the positive control. When
Vero cells were challenged with DENV-2 in the presence
of inhibitors of miRNA-133a, we found no difference
compared to the DENV-2-infected cells. To confirm that
miRNA-133a negatively influences DENV replication,
viral RNA copies were quantified in the cell culture su-
pernatants (Fig. 3b). A 3 log reduction in viral RNA copy
number was seen in cells overexpressing miRNA-133a at
72 hpi. We also observed a 10-fold reduction in viral
titer at 72 hpi, using flow cytometry (Fig. 3c). Taken to-
gether, our results indicate that overexpression of host
miRNA-133a potently suppresses DENV-2 replication.
DENV-2 infection up-regulates the expression of PTB at
early stages of infection; miRNA-133a represses PTB
Since the PTB mRNA contains the miRNA-133a tar-
get sequence [34, 38], we evaluated the expression
level of PTB in Vero cells with and without prior
transfection of miRNA-133a by western blot. As
shown in Fig. 4a, overexpression of synthetic miRNA-
133a suppressed PTB expression.
It was previously reported that in infected cells,
PTB moves from the nucleus to the cytoplasm and
contributes to DENV replication [35, 37]. Thus, we
evaluated whether DENV infection alters the level of
expression of this protein. According to previous re-
ports increased PTB expression was observed in
DENV-2 infected Vero cells at 12 hpi, compared to
uninfected cells (Fig. 4b). Based on this result and
since it is known that PTB plays a vital role during
DENV replication, we examined if PTB expression is
down-regulated in DENV-infected Vero cells overex-
pressing miRNA-133a. We found a slight decrease in
the level of PTB expression at 12 hpi (Fig. 4d and e),
but the expression was slightly increased at 24 and 48
hpi. Taken together, our results suggest a possible re-
lationship between DENV infection, miRNA-133a,




Fig. 3 miRNA-133a suppresses DENV-2 replication. Vero cells were transfected with the synthetic form of miRNA-133a or with the miRNA-133a
inhibitor as mimic, both at a final concentration of 50 μM. At 24 hpt, cells were challenged with DENV-2 at a MOI of 3 and infection was
evaluated at 12, 24, 48 and 72 hpi. a Flow cytometry of DENV-2 challenged cells, miRNA-133a transfected and infected cells, and miRNA inhibitor
transfected and infected cells. b Viral RNA copy number of DENV-2 infected cells, miRNA-133a transfected and infected cells, and miRNA inhibitor
transfected and infected cells assessed by RT-PCR in culture supernatants. c Viral titer of DENV-2 infected cells, miRNA-133a transfected and
infected cells, and miRNA inhibitor transfected and infected cells assessed by flow cytometry. Data are shown as median ± range from three
repeated experiments. (*) Statistically significant difference compared to the control (p < 0.05)
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MiRNA-133a expression is down-regulated by DENV-1 to
−4 at early stages of infection
To investigate if Vero cells express miRNA-133 we
next determined the endogenous expression (CT)
level of miRNA-133a in Vero cells by RT-qPCR. The
results show that Vero cells indeed express miRNA-
133a (Additional file 3). Therefore, we next aimed to
investigate if miRNA-133a is regulated during DENV
infection. To this end we challenged Vero cells with
DENV-1, −2, −3 or −4 at a MOI of 3 per cell and
quantified the endogenous expression of miRNA-133a
at 8, 16, 24, 32, 48 and 72 hpi by RT-qPCR. To
analyze the effect of DENV infection on miRNA-133a
expression, we normalized the fold-change of miRNA-
133a in Vero cells challenged with DENV to unin-
fected Vero cells and to 18S RNA (ΔΔCt; Additional
file 3). Although the extent of down-regulation for
each serotype varied, the level of expression of miR-
133a decreased in infected cells during the first 8 hpi
(Fig. 5). Repression of miRNA-133a expression inten-
sified at 16 hpi for DENV-2 and continued for
DENV-1 till 24 h, whereas in the case of DENV-4
and DENV-3 infection, the level of miRNA-133a in-
creased back to the basal level. The largest change
was observed at 16 hpi for all serotypes, highlighting
a 22-fold decrease induced by DENV-2. At later time
points, the expression of miRNA-133a recovered and
up-regulation occurred in the presence of all DENV
serotypes (Fig. 5). These results show that all four
DENV serotypes down-regulate the expression of
miRNA-133a early in infection, suggesting that this





Fig. 4 DENV up-regulates the expression of PTB through negative regulation of miRNA-133a. Vero cells were transfected with the synthetic form
of miRNA-133a at a final concentration of 50 μM or 100 μM, and 24 h post-transfection PTB expression was assessed by Western blotting (a). Vero
cells were challenged with DENV-2 NGC with a MOI of 3. PTB expression was measured by Western blotting at 12, 24 and 48 hpi (b). Finally, Vero
cells were transfected with the synthetic form of miRNA-133a at a final concentration of 100 μM, and 24 hpt were challenged with DENV-2 at a
MOI of 3. PTB expression was then measured by western blotting at 12, 24, 48 and 72 h (d). For (a, b), tubulin was used as loading control; for
(d), actin was used as loading control. Semi-quantitative data of the western blot was assessed using Image J (c, e)
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The 3′UTR of DENV inhibits the expression of miRNA-133a
It has been reported that sfRNA, derived from the 3′
UTR, is abundantly expressed during flavivirus infection
in cultured cells [39]. It was described to function as an
RNAi suppressor during virus replication through inter-
ference with the processing of the dsRNA template by
Dicer [6]. Consequently, the involvement of the 3′UTR
of DENV RNA in down-regulation of miRNA-133a ex-
pression was investigated. The 3′UTR of DENV-1, −2
and 4 was cloned into the pEGFP-C1 plasmid and the
constructs obtained were used to transfect Vero cells. As
controls, the empty pEGFP-C1 vector, as well as non-
transfected cells were used. Expression of miRNA-133a
was evaluated at 12, 24, 48 and 72 h post-transfection
(hpt) by RT-qPCR and the expression was normalized to
the non-transfected control cells and to 18S RNA . As
shown in Fig. 6, the 3′UTR of DENV-1, −2, and −4 in-
duced a strong decrease of more than 6-fold in the ex-
pression of miRNA-133a at all the time points
examined, with the exception of the 3′UTR of DENV-2
at 48 hpt. The 3′UTR of DENV-2 induced the highest
down regulation with a 30-fold change at 12 hpt (Fig. 6).
Discussion
Cellular miRNAs participate in the life cycles of many vi-
ruses [13, 14, 32], including DENV [40]. In this study we
demonstrate that overexpression of miRNA-133a impairs
DENV-2 replication, affecting both the percentage of in-
fected cells and the number of produced viral RNA copies.
Although it is not clear how miRNA-133a alters DENV
replication we propose that, based on our bioinformatic
screening, miRNA133a directly binds to a sequence local-
ized in the 3′SL loop of the 3′UTR. This loop contains
the 3′CS and 3′UAR elements that are required for gen-
ome circularization and viral viability [41–43]. This hy-
pothesis is strengthened by the results obtained with the
3′UTR-GFP DENV plasmids. Further studies are needed
to confirm this hypothesis, as well as to determine which
mechanisms are used by miRNA-133a to regulate DENV
infection.
Interestingly, miRNA-548 g-3p was recently reported
to bind to the stem loop A (SLA) promoter in the
DENV 5′UTR, a very important element involved in
DENV replication, and inhibits DENV replication [21].
Both, DENV 3′UTR and 5′UTR contain sequences that
are implicated in translation, replication and cyclisation.
Furthermore, the UTR of DENV interacts with cellular
proteins, including PTB [36, 44]. PTB has been impli-
cated in multiple steps of pre-mRNA processing, polya-
denylation regulation, and viral/cellular IRES-dependent
translation of RNA [45–50]. In Vero cells, silencing of
PTB expression alters both virus translation and replica-
tion whereas overexpression of PTB increases DENV
propagation [35]. PTB binds specifically to the con-
served sequence 1 and long stem-loop structures of the
3′UTR of DENV [44] and promotes viral RNA replica-
tion, possibly by acting as a RNA helicase [35, 37, 44].
Here we observed that PTB expression is increased in
Vero cells challenged with DENV, with a peak of expres-
sion at 12 hpi, indicating that the regulation occurs early
Fig. 5 DENV infection induces down-regulation of miRNA-133a. Vero
cells were infected with DENV-2 at a MOI of 3. miRNA-133a expression
was evaluated at 8, 16, 24, 32, 48, 72 hpi by RT-PCR and normalized to
an uninfected control and to the 18S RNA (ΔΔ Ct). Data are shown as
median ± range from three repeated experiments
Fig. 6 The expression of miRNA-133a is regulated by the 3'UTR of
DENV. Vero cells were transfected with a pEGFP plasmid carrying the
3'UTR of DENV-1, −2, or −4. miRNA-133a expression was evaluated at
12, 24, 48 and 72 hpt by RT-PCR and normalized to an untransfected
control and to the 18S RNA (ΔΔ Ct). Data are shown as median ±
range from three repeated experiments. (*) Statistically significant
difference compared to the control (p < 0.05)
Castillo et al. BMC Infectious Diseases  (2016) 16:29 Page 9 of 12
in infection. Interestingly, DENV-infected Vero cells
overexpressing miRNA-133a clearly showed a marked
reduction in PTB expression at 12 hpi, whereas at later
times (24, 48 hpi) a slight increase expression was ob-
served. Therefore we hypothesize that PTB is crucial in
the first hours of viral replication. The virus may induce
down-regulation of miRNA-133a in order to maintain
high levels of PTB early in infection thereby facilitating
viral replication. Based on these results and since previ-
ous reports show that miRNA-133a inhibits PTB mRNA
translation by binding to the 3-UTR of the PTB mRNA
[33, 34], we suggest that lower levels of PTB alter the
circularization of DENV RNA, an essential step for
DENV RNA translation and RNA synthesis. Our hy-
pothesis is that miRNA-133a acts as an anti-DENV
agent and this is supported by the fact that all four sero-
types of DENV are able to decrease the endogenous ex-
pression of miRNA-133a in Vero cells early in infection.
We did not observe cell death, however there is a possi-
bility that overexpression of miRNA-133a has cytotoxic
effects and the observed antiviral activity may be due to
an indirect phenomenon. The biological consequence
of such changes in miRNA-133a levels is unknown,
but we propose that it can induce PTB expression,
and in turn promote DENV replication, as previously
reported [44]. In fact, PTB depletion and PTB inhib-
ition was previously reported to reduce DENV repli-
cation, suggesting an important role for this protein
in the DENV life cycle [37].
Several studies described the pathway by which DENV
down-regulates the expression of cellular miRNAs. For ex-
ample, NS4B was described to act as a potent RNAi sup-
pressor [51]. Furthermore, for West Nile virus, sfRNA was
described to suppress the siRNA- and miRNA-induced
RNAi pathway [6]. Our results suggest a role for the 3′
UTR of DENV RNA in the regulation of cellular miRNA
expression. Although this is a novel report showing a link
between DENV infection and host miRNA, there is a
growing number of studies on the function of the
miRNA/RNAi machinery in DENV replication [52–54].
These data support the idea that noncoding sequences of
DENV such as the 3′UTR might be involved in miRNA
synthesis, as we report here. Furthermore, sfRNA derived
from the Flavivirus 3′UTR is involved in inhibiting the
antiviral activity of type II IFN and in suppressing RNAi
activity in insect and mammalian cells [55].
Several viral factors have been described that can in-
hibit the RNAi machinery. The HIV-1 Nef, an accessory
protein, interacts with Ago2 protein and function as a
suppressor of RNAi [56]. Also, the HIV-1 proteins Tat
and Rev can suppress Dicer-dependent RNA silencing
through RNA binding proteins that contain arginine-
rich motifs (the short arginine-rich linear motif of the
HIV-1 regulatory proteins inhibits Dicer-dependent
RNA interference). For DENV, the NS4B protein has
RNAi suppressor activity [51]. These data together with
data from others [6], show that mammalian viruses,
similar to insect and plant viruses, encode for proteins
or RNA sequences with RNAi silencing suppression
(RSS) activity. Our data also suggest that an RSS role for
the 3′UTR of DENV will be assigned. Although the data
of our study can lead to understanding further the func-
tion of miRNA-133a in DENV replication, further stud-
ies are needed to better understand the biological
significance of our results and their application as an
antiviral strategy. Particularly, the study of miRNA-133a
expression changes in response to DENV infection in
DENV targets cells could provide very interesting clues
about the host factors that are involved during DENV
infection.
Conclusions
In conclusion, we report for the first time the involve-
ment of miRNA-133a in modulating DENV-2 replica-
tion, possibly by altering the expression of host factors
such as PTB. In addition we found that infection of Vero
cells with each of the 4 DENV serotypes or plasmid con-
struct encoding the 3′UTR of DENV RNA transfection
resulted in decreases expression of miRNA-133a.
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